# Patient-reported outcomes after upper-extremity deep vein thrombosis due to compression syndromes: a multinational longitudinal retrospective study

**Authors:** Maya Abrishami Kashani, Domenico Baccellieri, Mert Dumantepe, Naomi Elbaranes, Nicolas Gendron, Marianna Gigliotti De Fazio, Egidio Imbalzano, Lina Khider, Nils Kucher, Corrado Lodigiani, Benedetta Madaro, Saskia Middeldorp, Clara Sacco, Yasmine Terbeche, Ferdinando Benito Attilio Valente, Stefano Barco

PMC · DOI: 10.1016/j.rpth.2026.103358 · 2026-01-16

## TL;DR

This study finds that upper-extremity deep vein thrombosis can lead to lasting symptoms and reduced quality of life in patients, even after treatment.

## Contribution

The study provides new insights into patient-reported outcomes following UEDVT due to compression syndromes, highlighting symptom persistence and its impact on quality of life.

## Key findings

- Nearly two-thirds of patients reported persistent symptoms like swelling and heaviness after UEDVT.
- UEDVT was linked to mild disability in upper-limb function and reduced quality of life.
- Persistent symptoms were the main predictor of residual functional impairment.

## Abstract

There are limited data on functional and patient-reported outcomes after acute upper-extremity deep vein thrombosis (UEDVT) caused by compression syndromes.

This study examined patient-reported functional impairment, quality of life, and treatment satisfaction after UEDVT.

We did a retrospective multicenter cohort study of patients with confirmed UEDVT due to compression syndromes not related to central lines. Patients were included at 5 centers in 4 countries and completed a standardized patient-reported outcome survey. The primary outcome was upper-limb function measured via the Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) score (range, 0-100; higher scores indicate worse function) during follow-up. Quality of life was assessed using a Visual Analogue Scale. Additional outcomes included persistent symptoms, treatment satisfaction, mental health impact, and perception of unmet needs.

We included 82 patients (median age, 38 years; Q1-Q3, 26-48 years); 44% were women. All patients received anticoagulation, and 66% underwent catheter-directed therapy. First-rib resection was performed in 24% of patients. After a median follow-up of 16 months, 63% reported ≥1 persistent symptom, most commonly swelling (30%) and heaviness (29%). The median QuickDASH score was 8 (Q1-Q3, 2-20), indicating mild overall disability. QuickDASH correlated negatively with quality of life (Spearman ρ = −0.82; P < .001) and across QuickDASH items and countries. Symptom persistence emerged as the main predictor of residual functional impairment. Patient-reported priorities included maintaining adequate arm function (78%) and avoiding recurrent UEDVT (73%).

UEDVT can have lasting functional and psychosocial effects. Patient-reported outcomes reveal a burden that is not captured by traditional clinical metrics and should be integrated into routine care as well in the setting of interventional trials.

•Upper-extremity deep vein thrombosis (UEDVT) affects healthy, active patients.•Patients from 5 hospitals in 4 countries completed a standardized outcomes survey.•Nearly two-thirds had lasting arm symptoms, mainly swelling and heaviness.•Ongoing symptoms were linked to worse arm function and quality of life.

Upper-extremity deep vein thrombosis (UEDVT) affects healthy, active patients.

Patients from 5 hospitals in 4 countries completed a standardized outcomes survey.

Nearly two-thirds had lasting arm symptoms, mainly swelling and heaviness.

Ongoing symptoms were linked to worse arm function and quality of life.

## Full-text entities

- **Diseases:** swelling (MESH:D004487), compression syndromes (MESH:D009408), functional impairment (MESH:D003072), UEDVT (MESH:D056824)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907070/full.md

---
Source: https://tomesphere.com/paper/PMC12907070